

Autoinjectors

Devices, Therapeutic Markets, Strategies and Prospects



Autoinjectors: Devices, Therapeutic Markets, Strategies and Prospects

Greystone Associates is pleased to announce the publication of a new market study. **Autoinjectors: Devices, Therapeutic Markets, Strategies and Prospects** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for autoinjectors designed to accept a prefilled syringe and simplify the injection process for self-administration. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Converging Factors Driving the Growth of Autoinjectors

The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives. For drugs developed for self-administration, autoinjectors have been shown to provide a more user-friendly outer package and improved compliance. While autoinjectors are sometimes designed to work with a particular injectable product as a form of pharmaceutical branding, the typical autoinjector is designed to fit one or more standard sizes of prefilled disposable syringes. Until recently, autoinjectors were designed to be reused. The reason was that the injectors were too expensive to be successfully marketed as a throw-away device. Recent improvements in materials technology and device design have led to the creation of a class of autoinjectors that can be made economically in high production quantities, opening the door for the disposable autoinjector, and providing expanded opportunities for both patient and drug marketer.

Report Value Matrix




Table of Contents

Executive Summary

Injectable Drug Delivery Market Dynamics

- The Economics of Injectable Drugs
- What's Driving the Growth in Autoinjectors?
 - Prefilled Syringes Proliferating
 - The Trend toward Self-Administration
 - Shifting Demographics
 - Innovation in Disposable Device Designs
- Therapeutic Demand Drivers
- Competitive Landscape
- Risk Factors

Autoinjectors – Commercial Devices

- Manual injection Autoinjectors
- Automated Injection Autoinjectors
- Reusable Autoinjectors
- Disposable Autoinjectors
- Bundled (Pre-assembled) Autoinjectors
- Product Specific Autoinjectors
- Novel Autoinjection Feature Designs

Autoinjector Device Design Factors

- Material Selection Issues
- Part Counts and Device Cost
- Safety Features
 - Needle Shielding
 - Needle Insertion Depth
 - Failsafe Activation
 - Dose Inspection/Injection Confirmation
- Lyophilized Drugs/Reconstitution
- Human Engineering/Ergonomics

Autoinjector Drug Delivery – Key Therapeutic Sector Analysis

- Anemia
- Anticoagulants
- Autoimmune Diseases
 - Rheumatoid Arthritis
 - Multiple Sclerosis
 - Psoriasis
- Diabetes
- Emergency Medicine
- Hepatitis
- Hematopoietics
- Hormones
- Reproductive Health

Market Factors

- Regulatory Issues
- Device Branding
- Patient Compliance
- Healthcare Economics
- Ease of Use

Autoinjector Devices - Company Profiles

Feature Summary

- Provides detailed analysis of autoinjectors for injectable drug delivery, and assesses key market segments, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates commercial devices in five key product segments
- Analyzes design factors, material selection issues, technologies and market development issues
- Charts product data, market share, and forecasts to 2013
- Profiles injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of pharma-device alliances and design partnerships on autoinjector commercialization and market access
- Evaluates the impact of economic, technology, and regulatory factors

Report Format and Availability

This report is available electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Autoinjectors: Devices, Therapeutic Markets, Strategies and Prospects

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$2,850.00	
<input type="checkbox"/>	Site License	\$3,850.00	
<input type="checkbox"/>	Enterprise License	\$5,500.00	
Total Payment (U.S. funds)			



Method of Payment: ___ Company Check ___  ___  ___  ___ Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
Name:	Name: <input type="checkbox"/> Click here if same as Billing Information
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: